Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III (PAOLA) study.

CONCLUSIONS: In this patient population with a high burden of comorbid illness, pasireotide was well tolerated and efficacious, providing prolonged maintenance of biochemical control and improving symptoms.
PMID: 32217809 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - February 29, 2020 Category: Endocrinology Authors: Colao AAL, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR Tags: Eur J Endocrinol Source Type: research